MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.

CIK 0001823239 49 ready 8-Ks latest June 3, 2026, 8:31 AM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline Risk accumulating: auditor change (2)

Ready 8-Ks 49

Latest filing June 3, 2026, 8:31 AM ET

Top materiality 0.90

Event mix earnings ×19 · leadership ×12 · other_material ×10

Sentiment 11 pos · 13 neg · 25 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for MRVI

Highest-materiality recent filing

Maravai Q2 revenue down 32% to $47.4M; net loss $69.8M; restructuring cuts 25% of workforce

August 11, 2025, 7:59 PM ET earnings materiality 0.90 negative item 2.02 item 2.05 item 5.02 item 9.01 ◈ Restructurings & Charges

Q2 revenue $47.4M (-32% YoY); net loss $69.8M (incl. $30.4M goodwill impairment); adjusted EBITDA -$10.4M vs +$13.0M.
Announced restructuring targeting >$50M annualized savings; workforce reduction of ~25% with $8-9M severance costs.

Read filing →

June 3, 2026, 8:31 AM ET debt materiality 0.65 positive item 1.01 item 1.02 item 2.03 item 7.01 item 9.01 ◈ Debt Financings ×2◈ Material Agreements ×2

Maravai LifeSciences refinances credit agreement, reduces debt by ~$93M and extends maturity to 2032

New $150M term loan and $30M revolver mature June 2032; proceeds plus $98.5M cash repaid $242.9M prior debt due Oct 2027.
May 7, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Maravai LifeSciences Q1 revenue up 41% to $65.8M; raises full-year guidance

Q1 2026 revenue $65.8M, up 40.5% YoY; net loss improved to $(6.4)M from $(52.9)M.
February 25, 2026, 6:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01

Maravai Q4 revenue $49.9M, net loss $63M; guides 2026 revenue $200-210M

Q4 revenue $49.9M, net loss $(63.0)M, positive Adj EBITDA $0.5M (non-GAAP).
November 6, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Maravai Q3 revenue $41.6M, net loss $45.1M, Adj EBITDA -$10.8M

Revenue of $41.6 million, net loss of $45.1 million, and Adjusted EBITDA loss of $10.8 million for Q3 2025.
August 11, 2025, 7:59 PM ET earnings materiality 0.90 negative item 2.02 item 2.05 item 5.02 item 9.01 ◈ Restructurings & Charges

Maravai Q2 revenue down 32% to $47.4M; net loss $69.8M; restructuring cuts 25% of workforce

Q2 revenue $47.4M (-32% YoY); net loss $69.8M (incl. $30.4M goodwill impairment); adjusted EBITDA -$10.4M vs +$13.0M.
July 18, 2025, 7:59 PM ET other material materiality 0.65 negative item 4.01 item 9.01 ◈ Auditor Changes ×2

Maravai LifeSciences dismisses EY, appoints Deloitte; material weakness disclosed

EY dismissed as auditor; Deloitte appointed effective July 16, 2025 for FY 2025.
June 9, 2025, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Maravai LifeSciences appoints Bernd Brust as CEO, succeeding William Martin

Bernd Brust named CEO and board member effective June 8, 2025; William Martin resigned as CEO and from board.
May 12, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01

Maravai Q1 revenue $46.9M (-27% YoY), net loss $(52.9)M, adj EBITDA $(10.5)M

Revenue $46.9M vs $64.2M in Q1 2024; net loss $(52.9)M includes $12.4M goodwill impairment.
March 20, 2025, 7:59 PM ET other material materiality 0.75 neutral item 7.01

Maravai LifeSciences guides 2025 revenue $185M-$205M; Q1 revenue $43M-$45M

Full-year 2025 revenue guidance $185M-$205M; Q1 2025 revenue $43M-$45M.
March 18, 2025, 7:59 PM ET other material materiality 0.85 negative item 2.02 item 4.02 item 9.01

Maravai restates Q2/Q3 2024 financials due to $3.9M revenue recognition error; Q4 revenue down 24%

Non-reliance on Q2 and Q3 2024 financials; restatement corrects $3.9M revenue timing error.
February 25, 2025, 6:59 PM ET other material materiality 0.75 negative item 2.02 item 7.01 item 9.01

Maravai postpones Q4/FY2024 earnings, cites material weakness in revenue recognition and potential goodwill impairment

Earnings release and call postponed; 10-K filing delayed until March 18, 2025.
December 18, 2024, 6:59 PM ET debt materiality 0.65 positive item 8.01

Maravai prepays $228M of term loan; remaining balance ~$300M

Voluntarily prepaid $228M aggregate principal of term loan using cash on hand.
December 5, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 7.01 item 9.01

Maravai LifeSciences Chairman Carl Hull Retires; R. Andrew Eckert Appointed Chairman

Founder Carl Hull retires as Executive Chairman and resigns from Board, effective Dec 5, 2024; departure not related to any disagreement.
November 7, 2024, 6:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01

Maravai reports Q3 loss of $176M on $154.2M goodwill impairment; acquires Officinae Bio DNA/RNA business

Q3 revenue $65.2M (down 2.5% YoY); net loss $(176.0)M includes $154.2M goodwill impairment.
August 7, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Maravai Q2 revenue up 6.5% to $73.4M, net loss $14.5M; reaffirms FY2024 guidance

Q2 revenue $73.4M (+6.5% YoY); Nucleic Acid Production +9.8%, Biologics Safety Testing -4.7%.
May 8, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Maravai Q1 revenue down 19% to $64.2M; net loss widens to $22.7M; FY guide reaffirmed

Quarterly revenue $64.2M, down 19% YoY; Nucleic Acid Production fell 25% to $46.0M.
February 22, 2024, 6:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01 ◈ Earnings Releases ×4

Maravai Q4 revenue plunges 64% to $74.1M; net loss $110M; FY24 guidance $265-285M

Revenue $74.1M (down 64% YoY); net loss $110M vs net income $87.4M year ago.
November 7, 2023, 6:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01 ◈ Earnings Releases

Maravai Q3 revenue down 65% to $66.9M, net loss of $15.1M; cuts ~100 jobs to save $30M annually

Q3 revenue $66.9M (-65% YoY); net loss $15.1M vs net income $99.7M a year ago.
August 7, 2023, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases ×3

Maravai Q2 revenue $68.9M, down 72%; net loss $11.9M; CEO transition to Trey Martin

Revenue $68.9M, down 71.6% YoY; net loss $(11.9)M vs net income $156.7M prior year.
July 27, 2023, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Maravai LifeSciences completes planned CEO succession; Martin becomes CEO, Hull Executive Chairman

William 'Trey' Martin, III named CEO effective July 27, 2023; previously President of Biologics Safety Testing segment.
May 8, 2023, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Maravai Q1 revenue $79M, down 68% YoY; net loss $1.3M vs prior net income $146.9M

Revenue $79.0M, -67.7% YoY; net loss $(1.3)M vs net income $146.9M in Q1 2022.
March 13, 2023, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change ×2

Maravai LifeSciences COO Brian Neel Resigns; Andrew Burch Named Successor

Brian Neel resigned as COO, Nucleic Acid Production, effective March 31, 2023.
March 10, 2023, 6:59 PM ET other material materiality 0.60 positive item 7.01

Maravai LifeSciences confirms no exposure to Silicon Valley Bank

Company has no cash deposits or securities at Silicon Valley Bank.
February 22, 2023, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases ×3

Maravai Q4 revenue $204.7M, adj EPS $0.35; 2023 guidance $420-460M; acquires Alphazyme

Q4 revenue $204.7M (-10% YoY); net income $87.4M; adjusted diluted EPS $0.35.
December 1, 2022, 6:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Maravai settles noncompete lawsuit; Martin to become President, then CEO in July 2023

Trey Martin to serve as President of Biologics Safety Testing segment from Dec 5, 2022.
November 2, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Maravai Q3 revenue $191.3M, down 7% YoY; net income $99.7M; guidance updated

Q3 revenue $191.3M (-6.6% YoY); net income $99.7M vs $132.2M prior year.
October 19, 2022, 7:59 PM ET leadership materiality 0.80 negative item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

CEO Trey Martin placed on paid leave after court-ordered noncompete TRO; Carl Hull named interim CEO

Delaware Court of Chancery issued TRO preventing Martin from working for Maravai; pending preliminary injunction hearing later this year.
October 3, 2022, 7:59 PM ET leadership materiality 0.70 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Maravai names Trey Martin CEO, co-founder Carl Hull becomes Executive Chairman

Martin appointed CEO effective Sept 30, 2022, succeeding Carl Hull who becomes Executive Chairman.
August 4, 2022, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Maravai Q2 revenue $242.7M (+11% YoY), net income $156.7M (+17%), Adj. EBITDA margin 78% record

Q2 revenue $242.7M (+11% YoY); net income $156.7M (+17%); Adj. EBITDA $188.5M (78% margin).
May 5, 2022, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Maravai Q1 revenue $244.3M (+65% YoY); net income $146.9M; raises FY22 guidance

Record Q1 revenue $244.3M, up 65% YoY; Nucleic Acid Production $223.7M (+80%).
February 23, 2022, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Maravai Q4 revenue $228M, up 132% YoY; net income $127M; 2022 guidance raised to $920-960M

Q4 revenue $228.4M (+132% YoY); net income $127.1M (+778% YoY).
January 28, 2022, 6:59 PM ET M&A materiality 0.80 positive item 7.01 item 9.01

Maravai acquires MyChem for $240M cash; expands ultra-pure nucleotides for mRNA therapeutics

Purchase price $240M cash at close plus contingent consideration based on future conditions.
November 10, 2021, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Maravai Q3 revenue up 133% to $204.8M; raises 2021 guidance, provides 2022 outlook

Q3 revenue $204.8M (+133% YoY); net income $132.8M (+240%); Adj EBITDA $156.0M.
August 10, 2021, 7:59 PM ET earnings materiality 0.80 positive item 1.01 item 2.02 item 9.01

Maravai Q2 revenue up 364% to $217.8M, raises FY guidance to $745-770M; selling Vector for $124M

Q2 revenue $217.8M (+364% YoY); net income $134.3M vs $1.4M; Adj. EBITDA $164.7M vs $17.5M.